# Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

> **NCT03076970** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 42 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** lasmiditan 200 mg
- **DRUG:** Sumatriptan
- **DRUG:** matching placebo

## Key facts

- **NCT ID:** NCT03076970
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-21
- **Primary completion:** 2017-04-13
- **Final completion:** 2017-04-13
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-12-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03076970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03076970, "Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03076970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*